Pfizer’s PCV20 offers single-shot protection against 20 pneumococcal serotypes, safeguarding adults from serious respiratory ...

Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal ...

A next-generation pneumococcal conjugate vaccine, PCV20, a single-dose protection is now available in India marking a new ...

Alongside its results, the company announced a significant product launch. On August 11, Pfizer rolled out its ...

Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...

Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine, PCV20, in India to provide protection against 20 serotypes of pneumococcal disease. The single-shot vaccine is aimed at adults, ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

Pfizer launches PCV20 for adults in India to offer broad protection against pneumococcal disease: Our Bureau, Mumbai Wednesday, August 13, 2025, 15:45 Hrs [IST] Pfizer has announc ...

PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker ...

PCV20 includes all 13 serotypes in PCV13, along with seven additional serotypes “that are responsible for a substantial amount of the residual disease burden,” he added.